Flow Cyt, MM Tumor cell killing
Flow Cyt 1/100; MMTumor cell killing
Purified from cell culture supernatant by affinity chromatography
|Formulation & Reconstitution||
Research use only
BiTE bispecific antibody is an Engineered fusion protein constructed from two single-chain variable fragments (scFvs) of different monoclonal antibodies. One of the scFvs will be constructed from an anti-CD3 monoclonal antibody, and the other scFv fragment which linked by a linker region will be made from an anti-Tumor cell specific monoclonal antibody.The B-cell maturation protein (BCMA or BCM) is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. [provided by RefSeq, Jul 2008]
Anti-BCMA bispecific antibody(DM16)
Price: 10μg $99.00 ; 100 μg $438.00 ; 500 μg $1314.00
Figure 1. The basic principle of BiTE cell killing assay. The BiTE molecule can effectively bring T cells to tumor target cells and stimulate tumor cell killing activity of T cells.
Figure 2. A: The scheme of Anti-BCMA BiTE molecule. B: Tumor cell killing assay. NCI-H929 cells (stably transfected with luciferase), were incubated with freshly isolated human PBMC, and different concentration of BiTE antibodies constructed from rabbit Anti-Human BCMA/TNFRSF17 Clone DM16 (red line), or BB2121 originated huC11D5.3 clone (blue line) or a no BCMA binding clone as negative control (black line). After 48hrs incubation, the viable NCI-H929 tumor cells were measured by luciferase activity assay.